A composite probiotic with the effect of regulating blood sugar and blood lipid in fish and its application

By combining Bacillus coagulans BC66, Bifidobacterium animalis BA20 and Pediococcus acidilacticic PA153, the problem of increased blood sugar and blood lipids in high carbohydrate feed was solved, and the fish was improved The utilization rate and growth performance of carbohydrates ensure the safety and long-term effect of the product.

CN118581019BActive Publication Date: 2024-12-03SUZHOU WEIKANG AGRICULTURAL BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411074907.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-12-03
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

After fish feeding high-carbohydrate feed, they experience significant increases in the levels of hyperglycemia, blood lipids and liver lipids, leading to fatty liver and nutritional metabolic diseases. The bioavailability of existing aquatic animals is low and prone to drug resistance. , limiting its widespread application.

Method used

By combining Bacillus coagulans BC66, Bifidobacterium animalis BA20 and Pediococcus lacticococcus acidilacticic PA153, three probiotic strains are used to promote the metabolism of fish sugar and lipids and improve the utilization of carbohydrates in feed rate, reduce blood sugar and liver lipid levels, and increase insulin levels.

Benefits of technology

It significantly improves the weight gain rate of fish, reduces liver ratio and fat content, improves blood sugar levels, enhances the blood sugar removal ability and insulin secretion of fish, and is highly safe and does not easily develop resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
Patent Text Reader

Abstract

The present invention relates to a composite probiotic having the function of regulating blood sugar and blood lipid in fish and its application. The composite probiotic having the function of regulating blood sugar and blood lipid in fish comprises Bacillus coagulans. Bacillus coagulans BC66 strain, Bifidobacterium animalis Bifidobacterium animalum BA20 strain and Pediococcus acidilactici Pediococcus acidilactici PA153 strain. The present invention found that the above three strains can cooperate with each other and promote each other, and play a synergistic effect in promoting fish glucose and lipid metabolism and improving fish's utilization of carbohydrates in feed, which is specifically reflected in: increasing fish weight gain rate; reducing fish liver-to-body ratio, fat content and blood sugar level; and increasing fish insulin level.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of probiotics and relates to a composite probiotic with the effect of regulating blood sugar and blood lipid of fish and application thereof. Background Art

[0002] In recent years, with the continuous development of aquaculture, the demand for aquatic feed has also increased. High-protein feed has increased the cost of breeding and caused nitrogen pollution to the aquaculture water environment. As one of the non-protein energy sources, carbohydrates are cheap and widely available. The use of appropriate levels can effectively solve the above problems. However, compared with mammals, fish have a poor ability to utilize carbohydrates and are considered to be born "diabetics". After eating high-carbohydrate feed, they will have persistent hyperglycemia symptoms. At the same time, there are also fatty liver phenomena such as significantly increased blood lipid and liver fat levels, liver hypertrophy, pale liver color, and increased hepatocyte vacuoles. These phenomena can cause nutritional metabolic diseases, which in turn lead to decreased growth or even death of fish.

[0003] At present, there are few reports on the development of glucose metabolism regulators for aquatic animals, and existing studies have mainly focused on the hypoglycemic effect of Western medicines. However, Western medicines can easily cause aquatic animals to develop drug resistance and drug residues during use, thus restricting their widespread use in feed. At the same time, the bioavailability of glucose metabolism regulators for aquatic animals currently sold on the market is low, which greatly limits their function.

[0004] Probiotics are a type of live microorganisms that are beneficial to the host body. They can improve and prevent diseases after taking a certain dose. Studies have found that probiotics and synbiotics can improve metabolic syndrome in adults with prediabetes. Probiotics are currently a forward-looking natural biological therapeutic agent with broad development prospects. Summary of the invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a composite probiotic having the effect of regulating blood sugar and blood lipids in fish and its application.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a composite probiotic having the effect of regulating blood sugar and blood lipids in fish, wherein the composite probiotic having the effect of regulating blood sugar and blood lipids in fish comprises Bacillus coagulans with a preservation number of CGMCC 21879. Bacillus coagulans BC66 strain, Bifidobacterium animalis with a deposit number of CGMCC No. 21830 Bifidobacterium animalum BA20 strain and Pediococcus acidilactici with a deposit number of CCTCC NO: M 2023230 Pediococcus acidilacticiPA153 strain.

[0008] The present invention creatively develops a new probiotic compounding method and a strategy for regulating blood sugar and blood lipid in fish, namely, Bacillus coagulans Bacillus coagulans BC66 strain, Bifidobacterium animalis Bifidobacterium animal BA20 strain and Pediococcus acidilactici Pediococcus acidilactici The PA153 strains were used in combination, and it was found that the three strains can cooperate and promote each other, and have a synergistic effect in promoting fish lipid metabolism and improving fish's utilization of carbohydrates in feed, which is specifically reflected in: (1) improving fish weight gain rate; (2) reducing fish liver-to-body ratio and fat content; (3) reducing fish blood sugar levels; (4) improving fish insulin levels. When the amount of bacteria used is the same, the combination of BC66 strain, BA20 strain and PA153 strain has a significantly better effect in promoting fish lipid metabolism and improving fish's utilization of carbohydrates in feed than the intervention method of selecting any two of the strains. Therefore, the use of this composite probiotic in aquaculture has a good prospect. At the same time, the above three bacteria are all probiotics, the product is highly safe, and it is not easy to produce resistance.

[0009] Preferably, the ratio of the number of viable bacteria of the BC66 strain, BA20 strain and PA153 strain is (1-10):(1-10):(1-10), wherein (1-10) can be selected as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc., and other specific point values ​​within this numerical range can be selected, which will not be described here one by one.

[0010] In a second aspect, the present invention provides a probiotic agent having the effect of regulating blood sugar and blood lipids in fish, wherein the probiotic agent contains the composite probiotics described in the first aspect.

[0011] Preferably, the total number of bacteria in the probiotic is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g, for example 1×10 9 CFU / g (CFU / mL), 1×10 10 CFU / g (CFU / mL), 2×10 10 CFU / g (CFU / mL), 5×10 10 CFU / g (CFU / mL), 8×10 10 CFU / g (CFU / mL), 1×10 11 CFU / g (CFU / mL), 5×10 11 CFU / g (CFU / mL), 1×10 12CFU / g (CFU / mL), 1×10 13 CFU / g (CFU / mL), 1×10 14 CFU / g (CFU / mL), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0012] Preferably, the dosage form of the probiotic includes lyophilized powder, tablet, granule or solution.

[0013] Preferably, the probiotic is in the form of a freeze-dried powder, which is prepared by a preparation method comprising the following steps:

[0014] The BC66 strain, the BA20 strain and the PA153 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a lyophilization protective agent and then freeze-dried to obtain BC66 bacterial powder, BA20 bacterial powder and PA153 bacterial powder; the BC66 bacterial powder, BA20 bacterial powder and PA153 bacterial powder are mixed according to a ratio to obtain the probiotic agent.

[0015] Preferably, the lyoprotectant is selected from any one or a combination of at least two of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.

[0016] In a third aspect, the present invention provides use of the composite probiotics described in the first aspect or the probiotic agent described in the second aspect in aquaculture.

[0017] In a fourth aspect, the present invention provides an aquatic animal feed, comprising a basic feed and the probiotic agent according to the second aspect.

[0018] In a fifth aspect, the present invention provides use of the composite probiotic described in the first aspect or the probiotic agent described in the second aspect in the preparation of a product for improving the sugar metabolism function of aquatic animals.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] The present invention creatively develops a new probiotic compounding method and a strategy for regulating blood sugar and blood lipid in fish, namely, Bacillus coagulans Bacillus coagulans BC66 strain, Bifidobacterium animalis Bifidobacterium animal BA20 strain and Pediococcus acidilactici Pediococcus acidilacticiThe PA153 strains were used in combination, and it was found that the three strains can cooperate and promote each other, and have a synergistic effect in promoting fish lipid metabolism and improving fish's utilization of carbohydrates in feed, which is specifically reflected in: (1) improving fish weight gain rate; (2) reducing fish liver-to-body ratio and fat content; (3) reducing fish blood sugar levels; (4) improving fish insulin levels. When the amount of bacteria used is the same, the combination of BC66 strain, BA20 strain and PA153 strain has a significantly better effect in promoting fish lipid metabolism and improving fish's utilization of carbohydrates in feed than the intervention method of selecting any two of the strains. Therefore, the use of this composite probiotic in aquaculture has a good prospect. At the same time, the above three bacteria are all probiotics, the product is highly safe, and it is not easy to produce resistance.

[0021] The BC66 strain involved in the present invention is classified as Bacillus coagulans Bacillus coagulans The depository is the General Microbiology Center of China Microorganism Culture Collection Administration, the deposit number is CGMCC 21879, the deposit date is March 8, 2021, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0022] The BA20 strain involved in the present invention is classified and named Bifidobacterium animalis Bifidobacterium animal The depository is the General Microbiology Center of China Microorganism Culture Collection Administration, the deposit number is CGMCC No. 21830, the deposit date is February 25, 2021, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0023] The PA153 strain involved in the present invention is classified and named as Pediococcus acidilactici PA153 Pediococcus lactic acid PA153, the preservation unit is China Center for Type Culture Collection, the preservation number is CCTCC NO: M2023230, the preservation date is March 02, 2023, and the preservation address is Wuhan University, Wuhan, China. DETAILED DESCRIPTION

[0024] In order to further explain the technical means and effects adopted by the present invention, the technical solution of the present invention is further described below in conjunction with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.

[0025] In the following examples, unless otherwise specified, the reagents and consumables used were purchased from conventional reagent manufacturers in the field; unless otherwise specified, the experimental methods and technical means used were conventional methods and means in the field.

[0026] The basic feed involved in the following examples was purchased from Fujian Tianma Technology Group Co., Ltd., and the model was seabass compound feed No. 0 feed.

[0027] The BC66 strain involved in the following examples is classified as Bacillus coagulans Bacillus coagulans The deposit date is March 8, 2021, and the deposit number is CGMCC 21879.

[0028] The BA20 strain involved in the following examples is classified and named Bifidobacterium animalis Bifidobacterium animal The deposit date is February 25, 2021, and the deposit number is CGMCC No. 21830.

[0029] The PA153 strain involved in the following examples is named as Pediococcus acidilactici PA153 Pediococcus lactic acid PA153, the deposit date is March 2, 2023, and the deposit number is CCTCC NO: M 2023230.

[0030] The culture medium involved in the following examples is as follows:

[0031] MRS medium (g / L): peptone 10g / L, beef extract 10g / L, glucose 15g / L, lactose 15g / L, yeast powder 5g / L, diammonium hydrogen citrate 2g / L, K2PO4·3H2O 2.6g / L, MgSO4·7H2O 0.1g / L, MnSO4 0.05g / L, Tween 80 1mL / L, cysteine ​​salt 0.5g / L.

[0032] Preparation Example

[0033] Provided are a BC66 bacterial powder product, a BA20 bacterial powder product and a PA153 bacterial powder product, and the preparation methods thereof are as follows:

[0034] (1) Inoculate 3% of the Bacillus coagulans BC66 strain, the Bifidobacterium animalis BA20 strain, and the Pediococcus acidilactici PA153 strain stored in a -80°C glycerol tube into 5 mL of sterile MRS medium, culture at 37°C for 12 h, and subculture twice to obtain activated strains; then, inoculate 5% of the activated strains into 50 mL of sterile MRS medium, culture at 37°C for 12 h, and obtain expanded culture fluid;

[0035] (2) The expanded culture solution was inoculated into 1000 mL of sterile MRS medium at a 3% inoculum volume and cultured at 37°C for 24 h to obtain three types of fermentation broths, and the concentrations of the broths were determined;

[0036] (3) The obtained fermented bacterial broth was centrifuged at 8000 r / min for 20 min at 4°C, the supernatant was discarded under sterile conditions, and the bacterial sludge was collected; the collected bacterial sludge was mixed with a 20% lactose aqueous solution at a volume ratio of 1:2 using a vortex machine to obtain a mixture of Bacillus coagulans BC66 and lactose, a mixture of Bifidobacterium animalis BA20 and lactose, and a mixture of Pediococcus acidilactici PA153 and lactose, respectively;

[0037] (4) The mixture was pre-frozen in a -80°C refrigerator for 3 h to obtain a pre-frozen live bacteria preparation; then, the pre-frozen live bacteria preparation was freeze-dried in a vacuum freeze dryer at a freeze-drying temperature of -50°C and a vacuum degree of 0.20 mBar for 48 h until completely dry to obtain Bacillus coagulans BC66 powder, Bifidobacterium animalis BA20 powder and Pediococcus acidilactici PA153 powder, which were then stored in a -4°C refrigerator for later use. Example 1

[0038] The present embodiment provides a composite probiotic agent, which is composed of Bacillus coagulans BC66 powder, Bifidobacterium animalis BA20 powder and Pediococcus acidilactici PA153 powder with a live bacteria count ratio of 1:1:1. Example 2

[0039] The present embodiment provides a composite probiotic agent, which is composed of Bacillus coagulans BC66 powder, Bifidobacterium animalis BA20 powder and Pediococcus acidilactici PA153 powder with a live bacteria count ratio of 5:4:3. Example 3

[0040] The present embodiment provides a composite probiotic agent, which is composed of Bacillus coagulans BC66 powder, Bifidobacterium animalis BA20 powder and Pediococcus acidilactici PA153 powder with a live bacteria count ratio of 2:6:8.

[0041] Comparative Example 1

[0042] This comparative example provides a composite probiotic agent, which is composed of commercially available bacteria ATCC7050 powder, animal Bifidobacterium BA20 powder and Pediococcus acidilactici PA153 powder with a live bacteria count ratio of 1:1:1.

[0043] Comparative Example 2

[0044] This comparative example provides a composite probiotic agent, which is composed of Bacillus coagulans BC66 powder and Bifidobacterium animalis BA20 powder with a live bacteria count ratio of 1:1.

[0045] Comparative Example 3

[0046] This comparative example provides a composite probiotic agent, which is composed of Bacillus coagulans BC66 powder and Pediococcus acidilactici PA153 powder with a live bacteria count ratio of 1:1.

[0047] Comparative Example 4

[0048] This comparative example provides a composite probiotic agent, which is composed of animal Bifidobacterium BA20 powder and Pediococcus acidilactici PA153 powder with a live bacteria count ratio of 1:1.

[0049] Test Case

[0050] To explore the effect of compound bacterial agents on fish intake of high-sugar feed:

[0051] (1) A total of 720 largemouth bass (each weighing approximately 5 g) were randomly divided into nine experimental groups and placed in 36 cages (specifications: 2.0 m × 1.0 m × 1.0 m), with 20 fish in each cage.

[0052] (2) Experimental groups: There were 9 groups in total, namely: control group, fed with basic feed (sugar level of 35%); high-sugar group, fed with high-sugar feed (the only difference between it and the basic feed was that the sugar level was 45%); S1 group, fed with high-sugar feed + composite probiotics prepared in Example 1 (the total number of viable bacteria in the mixed feed was 1×10 7 CFU / g); Groups S2-S7 were fed with high-sugar feed + composite probiotics prepared in Example 2-Comparative Example 4 (the total number of viable bacteria in the mixed feed was 1×10 7 CFU / g). Each group of compound probiotics was added into the feed and mixed evenly with a mixer.

[0053] (3) Experimental process: Before the experiment, all 36 cages were fed in exactly the same way. During the formal experiment, the feed amount was 2% of body weight, and the fish were fed once a day at 8:00 and 17:00. The water source was aerated tap water. The culture lasted for 12 weeks, during which the feeding and growth of largemouth bass were observed. After the culture was completed, blood and tissue samples were collected for subsequent index analysis.

[0054] (4) Evaluation indicators:

[0055] (4.1) The growth indexes of the fish were measured at the beginning and end of the experiment. The fish weight was measured using an electronic balance. The liver and intestine were observed after the fish were dissected. The liver was removed and weighed, and then quickly frozen with liquid nitrogen and temporarily stored in a -80℃ refrigerator.

[0056] Weight gain rate (%) = (W t -W0) / W0×100%;

[0057] Liver to body ratio (%) = G 肝 / G×100%;

[0058] Where: W0 is the weight of fish at the beginning of the experiment, g; W tG is the weight of fish at the end of the experiment, g; 肝 is the weight of fish liver, g; G is the weight of fish at the time of sampling, g.

[0059] (4.2) At the end of the experiment, the muscles, livers and viscera of the fish were defatted by Soxhlet extraction, and the fat was extracted and weighed.

[0060] Fat content = g 脂肪 / G;

[0061] Where: G 脂肪 is the weight of fish fat, g; G is the weight of fish at the time of sampling, kg.

[0062] (4.3) After the experiment, the fish were deprived of food for 24 hours. Three fish were randomly selected from each cage and blood was collected from the tail vein using a 1 mL syringe. The blood was dropped onto a blood glucose test strip and the blood glucose level was measured using a blood glucose meter (Sinocare GA-3 blood glucose meter).

[0063] (4.4) After the experiment, blood was drawn from the fish, coagulated naturally at room temperature for 15 min, centrifuged for about 20 min (2500 r / min), and the supernatant was collected. Insulin levels were detected using an insulin enzyme-linked immunosorbent assay (ELISA) kit (Shanghai ELISA Biotechnology Co., Ltd.).

[0064] (5) Test results:

[0065] The results are shown in Table 1. Under the same feeding conditions, the weight gain rate of fish in the high-sugar group was significantly lower than that in the control group, while the liver-to-body ratio, fat content, blood sugar level, and insulin content of fish in the high-sugar group were significantly higher than those in the control group, indicating that largemouth black bass fed with high-sugar feed had liver fat accumulation, decreased tissue insulin sensitivity, and persistently high blood sugar, but the weight gain rate was significantly decreased.

[0066] The liver fat content and blood sugar level of each probiotic intervention group were significantly lower than those of the high-sugar group, but the weight gain rate and plasma insulin level increased. This shows that the feed containing compound bacteria can improve the liver fat accumulation caused by eating high-sugar feed in largemouth bass, enhance the blood sugar clearance ability of fish and promote insulin secretion, thereby increasing the weight gain rate of fish.

[0067] When the S4 group replaced Bacillus coagulans BC66 with the commercially available bacteria ATCC7050, its effect decreased compared with the S1 group; when the S5, S6 and S7 groups did not contain any of the three probiotics, Pediococcus acidilactici PA153, Bifidobacterium animalis BA20 and Bacillus coagulans BC66, their effects were significantly lower than those of S1, indicating that the three probiotics, Bacillus coagulans BC66, Pediococcus acidilactici PA153 and Bifidobacterium animalis BA20, have a synergistic effect in improving the hepatic fat accumulation caused by eating high-sugar feed in largemouth sea bass, enhancing the fish's blood sugar clearance ability and promoting insulin secretion.

[0068] Table 1

[0069]

[0070] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0071] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0072] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A probiotic agent having the effect of regulating blood sugar and blood lipid in fish, characterized in that: The strain in the probiotic is Bacillus coagulans with a deposit number of CGMCC 21879. Bacillus coagulans BC66 strain, Bifidobacterium animalis with a deposit number of CGMCC No. 21830 Bifidobacterium animalis BA20 strain and Pediococcus acidilactici with a deposit number of CCTCC NO: M 2023230 Pediococcus acidilactici PA153 strain composition; The ratio of the viable counts of the BC66 strain, the BA20 strain, and the PA153 strain is (1-10):(1-10):(1-10); The total number of bacteria in the probiotics is not less than 1×10 9 CFU / mL or 1×10 9 CFU / g.

2. The probiotic agent having the effect of regulating blood sugar and blood lipid in fish according to claim 1, characterized in that: The dosage form of the probiotics includes freeze-dried powder, tablets, granules or solutions.

3. The probiotic agent having the effect of regulating blood sugar and blood lipid in fish according to claim 2, characterized in that: The dosage form of the probiotic is a freeze-dried powder, which is prepared by a preparation method comprising the following steps: The BC66 strain, the BA20 strain and the PA153 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively, mixed with a lyophilization protective agent and then freeze-dried to obtain BC66 bacterial powder, BA20 bacterial powder and PA153 bacterial powder; the BC66 bacterial powder, BA20 bacterial powder and PA153 bacterial powder are mixed according to a ratio to obtain the probiotic agent.

4. The probiotic agent having the effect of regulating blood sugar and blood lipid of fish according to claim 3, characterized in that: The lyoprotectant is selected from any one or a combination of at least two of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.

5. Use of the probiotic according to any one of claims 1 to 4 in aquaculture.

6. A feed for aquatic animals, characterized in that: The aquatic animal feed comprises a basic feed and the probiotic agent according to any one of claims 1 to 4.

7. Use of the probiotic according to any one of claims 1 to 4 in the preparation of a product for improving the sugar metabolism function of aquatic animals.